Capricor Stock Soars 9%, Adding $48 Million After Its Cardiac Research Wins An Award
Deramiocel met its upper-limb trial goal, but a cardiac measure missed statistical significance and FDA approval remains pending.
Capricor Therapeutics, which develops cell therapies for Duchenne muscular dystrophy, soared 9.11% to $9.82 in Monday trading, as of 3:27 p.m. ET, adding $48 million in market value after its experimental treatment’s cardiac research won an award, the company announced Monday. Deramiocel still awaits an FDA approval decision.
Recognition Meets A Cardiac Caveat
The American Heart Association recognized the late-stage cardiac results with its pediatric cardiology research award. The trial followed 106 patients assigned to Deramiocel or placebo for 12 months and met its main goal of slowing deterioration in upper-limb function.
Across all patients, however, the difference in the heart’s pumping performance missed statistical significance. Deramiocel’s advantage over placebo was 1.8 percentage points; subgroup findings were not adjusted for multiple comparisons.
Capricor’s August 13 earnings release explained that peer review uncovered a statistical-model issue affecting that cardiac measure alone. Using the analysis plan established before researchers learned patients’ treatment assignments produced a p-value of 0.09, versus the previously reported 0.04, and a treatment difference of 1.8 percentage points rather than 2.4. The upper-limb result was unaffected, with a p-value of 0.029; the pre-specified cardiomyopathy subgroup’s p-value stayed at 0.02.
The FDA Question Is Different
The regulatory dispute concerns the heart-disease indication Capricor requested in 2024. On July 29, 2026, an FDA advisory committee voted against the evidence of effectiveness for treating cardiomyopathy in Duchenne patients, with 3 votes in favor and 9 against. Its recommendation is non-binding.
The committee was not voting on the trial’s main upper-limb goal or overall benefits and risks. Capricor said its discussion of upper-limb function was directionally supportive. The full results appeared in The Lancet in July.
Linda Marbán, Capricor’s chief executive officer, said in the August release: “We are continuing to work with the Agency on a path forward.”
Duchenne causes progressive damage to skeletal, respiratory and cardiac muscles. It primarily affects boys, and deterioration of the heart muscle can lead to cardiomyopathy and heart failure—the disease’s leading cause of death.
A Rebound Below The Peak
Monday’s advance was on pace to become Capricor’s fourth gain of 7% or more this month. The company’s market value stood at about $571 million in Monday trading, as of 3:27 p.m. ET.
Before Monday’s session, shares had gained 16% over the previous month but were still 75% below their highest close of the past year.
Capricor reported a second-quarter net loss of $40.7 million. It held approximately $238 million in cash, cash equivalents and marketable securities at June 30, 2026.
Management said its resources could cover operating needs for at least twelve months under its current plan. It expects to give longer-term financial guidance after gaining more regulatory clarity; that outlook excludes potential product sales, monetization of a priority review voucher if received, and other non-operating capital sources.
Capricor is scheduled to report earnings Tuesday, with Deramiocel’s FDA approval still pending.
Sources
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision — Yahoo Finance
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology — Yahoo Finance
- Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success — Yahoo Finance
- Hunting for the Next Biopharma Stock to Surge 700% — pro.thestreet.com
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel — globenewswire.com
- Capricor Therapeutics — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR
- Capricor Therapeutics — earnings release (Form 8-K, Item 2.02), filed 2026-08-13 — SEC EDGAR